Checkmate Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Barry A. Labinger
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 245 Main Street Cambridge MA United States of America 02142
- IPO Date
- Aug 7, 2020
- CIK
- 0001651431
- Website
- checkmatepharma.com
- Similar Companies
- Business
- Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company that develops proprietary immunotherapies to harness the power of the immune system against cancer. The company focuses on vidutolimod (CMP-001), an advanced Toll-like receptor 9 (TLR9) agonist delivered intratumorally via a virus-like particle encapsulating a CpG-A oligodeoxynucleotide; it is in Phase II trials combined with nivolumab for anti-PD-1 refractory melanoma, a randomized Phase II/III trial with nivolumab for first-line melanoma, Phase II with pembrolizumab for PD-1 refractory melanoma and head and neck cancer, and additional studies with cemiplimab for cutaneous squamous cell carcinoma and Merkel cell carcinoma, as well as other combinations for colorectal cancer and beyond. Founded in 2015 and headquartered in Cambridge, Massachusetts, Checkmate operates globally in oncology research and development, targeting patients with difficult-to-treat solid tumors through collaborations with leading checkpoint inhibitors from partners including Bristol Myers Squibb (nivolumab/Opdivo), Merck (pembrolizumab/Keytruda), Regeneron (cemiplimab/Libtayo), Merck KGaA, and Pfizer. In June 2022, Regeneron Pharmaceuticals acquired Checkmate for approximately $250 million in an all-cash deal at $10.50 per share, integrating vidutolimod into Regeneron's immuno-oncology portfolio to expand combination therapies for PD-1 refractory cancers; post-acquisition, Checkmate functions as a subsidiary while advancing its clinical pipeline without further public trading of its NASDAQ-listed CMPI shares.
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PSB, FSI, TWTR
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout
SHAREHOLDER ALERT: Weiss Law Investigates Checkmate Pharmaceuticals, Inc.
Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target
Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference